Clinical trial · Interventional
Multicenter Study of 9-Aminocamptothecin (9-AC) in Patients With Refractory Leukemia
Multicenter Study of 9-AC in Refractory Leukemia
NCT00251368CI-TRIAL-00004550completedPhase 1ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to evaluate the side effects of 9-Aminocamptothecin (9-AC) and to determine the best dose which should be used to treat leukemia.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Acute Lymphocytic Leukemia | Acute Lymphoblastic Leukemia | ALIAS | 0.90 |
| Leukemia, Myelocytic, Acute | Leukemia | ONTOLOGY_EXACT | 0.85 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| 9-Aminocamptothecin (9-AC) | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- To evaluate the toxicity and maximum tolerated dose of 9-AC administered as a 72 hour infusion in patients with relapsed/refractory leukemia.
- timeFrame
- Years
Secondary outcomes (1)
- measure
- To analyze the pharmacokinetics in these patients.
- timeFrame
- years
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * 18 years of age or older * AML or ALL in first or subsequent relapse, secondary AML, or CML in blastic phase * Central venous access * ECOG performance status of less than or equal to 2 * Bilirubin \< 1.3 * SGOT \< 2 x ULN * Alkaline phosphatase \< 2 x ULN * Creatinine \< 1.5 Exclusion Criteria: * Undergone bone marrow transplantation * Uncontrolled infection * Other active malignancy * HIV positivity * Serious medical or psychiatric illness * Pregnancy
References
Publications (0)
Data not yet available
No reference posted for this study.